- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01585623
Drug Interaction Study of SAR302503 in Patients With Solid Tumor
An Open-label, Two-treatment Crossover Pharmacokinetic Interaction Study of Repeated Doses of SAR302503 on Pharmacokinetics of a Single Dose Cocktail of Omeprazole, Metoprolol, and Midazolam Used as Probe Substrates for CYP2C19, CYP2D6 and CYP3A4 Activities, Respectively in Adult Patients With Refractory Solid Tumors
Primary Objective:
- To assess the effect of 15-day repeated oral doses of 500 mg SAR302503 on the cytochrome P450 activity using a CYP probe cocktail (2C19, 2D6 and 3A4).
- To document pharmacokinetics of SAR302503 after repeated 500 mg oral daily doses.
Secondary Objectives:
- To assess the safety profile of 15-day repeated oral doses of 500 mg SAR302503 in Segment 1
- To characterize the safety and tolerability of 28-day consecutive doses of 500 mg SAR302503 in Segment 2
- To determine antitumor activity in Segment 2
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Georgia
-
Augusta, Georgia, United States, 30912
- Investigational Site Number 840004
-
-
Michigan
-
Detroit, Michigan, United States, 48201
- Investigational Site Number 840001
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19111
- Investigational Site Number 840002
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria :
- Histologically or cytologically confirmed advanced solid malignancy that is metastatic or unresectable, and for which standard curative measures do not exist
- Signed informed consent
Exclusion criteria:
- Less than 18 years of age.
- Limited physical functioning (as evaluated by the Eastern Cooperative Oncology Group (ECOG) scale)
- Inability to follow study requirements and schedule
- Treatment of cancer within 3 weeks of study, concurrent treatment in another clinical trial or with any other anti-cancer therapy
- Serious medical illness at same time of study and/or significantly abnormal lab reports
- Lack of pregnancy contraception (women of childbearing potential), pregnancy, or breast feeding.
- Men who partner with a woman of childbearing potential, unless they agree to use effective contraception while on study drug
- Continued toxic effects of prior chemotherapy
- Evidence of other concurrent active malignancy
- Other concurrent serious illness or medical condition
- Cardiac abnormalities include bradycardia, AV block or other conduction defect on ECG, and patients taking a beta blocker.
- Patients with Insulin-Dependent Diabetes Mellitus.
- Patients with known active (acute or chronic) hepatitis A, B, C, and hepatitis B and C carries. Prior history of chronic liver disease (e.g., chronic alcoholic liver disease, autoimmune hepatitis, sclerosing cholangitis, primary biliary cirrhosis, hemachromatosis, non-alcoholic steatohepatitis [NASH]).
- Inadequate organ function
- History of partial or total gastrectomy, or, if in the opinion of the investigator, have any other disorder that would inhibit absorption of oral medications.
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Segment 1
two single doses of omeprazol/metoprolol/midazolam on day-1 and day 15 without food, SAR302503 500 mg once daily without food for 15 days
|
Pharmaceutical form:capsule Route of administration: oral Pharmaceutical form:capsule Route of administration: oral Pharmaceutical form:tablet Route of administration: oral Pharmaceutical form:solution Route of administration: oral |
EXPERIMENTAL: Segment 2
SAR302503 500 mg once daily without food in 28-day per cycle
|
Pharmaceutical form:capsule Route of administration: oral |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Omerprazole/metoprolol/midazolam - Pharmacokinetic parameter: AUC, AUClast
Time Frame: predose and up to 24 hours post dose on Days -1, 1, 15 and 16
|
predose and up to 24 hours post dose on Days -1, 1, 15 and 16
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Omerprazole/metoprolol/midazolam - Pharmacokinetic parameter : Cmax, Tmax, and t1/2z
Time Frame: predose and up to 24 hours post dose on Days -1, 1, 15 and 16
|
predose and up to 24 hours post dose on Days -1, 1, 15 and 16
|
SAR302503 - Pharmacokinetic parameter : Cmax, Tmax, Ctrough and AUC0-24
Time Frame: Day-1 to Day 16
|
Day-1 to Day 16
|
Clinical and laboratory events graded by the NCI CTCAE (National Cancer Institute Common Terminology Criteria for Adverse Events) v4.03 (Segment 1 and 2)
Time Frame: up to maximum 2 years
|
up to maximum 2 years
|
Objective response ratio (Complete response (CR) and partial response (PR)) (Segment 2)
Time Frame: up to 2 cycles ( i.e. 10 weeks)
|
up to 2 cycles ( i.e. 10 weeks)
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms
- Physiological Effects of Drugs
- Adrenergic beta-Antagonists
- Adrenergic Antagonists
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Antihypertensive Agents
- Central Nervous System Depressants
- Autonomic Agents
- Peripheral Nervous System Agents
- Anesthetics, Intravenous
- Anesthetics, General
- Anesthetics
- Tranquilizing Agents
- Psychotropic Drugs
- Hypnotics and Sedatives
- Adjuvants, Anesthesia
- Anti-Anxiety Agents
- GABA Modulators
- GABA Agents
- Sympatholytics
- Adrenergic beta-1 Receptor Antagonists
- Midazolam
- Metoprolol
Other Study ID Numbers
- INT12497
- U1111-1125-8930 (OTHER: UTN)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Solid Tumor
-
Memorial Sloan Kettering Cancer CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States, Puerto Rico
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States, Puerto Rico
-
Aadi Bioscience, Inc.RecruitingAdvanced Solid Tumor | Tumor | Tumor, SolidUnited States
-
RemeGen Co., Ltd.CompletedMetastatic Solid Tumor | Locally Advanced Solid Tumor | Unresectable Solid TumorAustralia
-
Sorrento Therapeutics, Inc.WithdrawnSolid Tumor | Relapsed Solid Tumor | Refractory Tumor
-
Impact Therapeutics, Inc.RecruitingSolid Tumor | Advanced Solid TumorChina, Taiwan, United States, Australia
-
Partner Therapeutics, Inc.WithdrawnSolid Tumor | Solid Tumor, AdultUnited States
-
Shenzhen Ionova Life Sciences Co., Ltd.Merck Sharp & Dohme LLCRecruitingCancer | Solid Tumor, Adult | Solid Carcinoma | Solid Tumor, Unspecified, Adult | Cancer Metastatic | Tumor, SolidUnited States
-
BeiGeneRecruitingSolid Tumor | Advanced Solid TumorUnited States, New Zealand, Australia, China
Clinical Trials on SAR302503
-
SanofiCompletedHematopoietic NeoplasmUnited States, Austria, Belgium, Canada, France, Germany, Italy, Netherlands, Spain, United Kingdom
-
SanofiCompleted
-
SanofiCompletedRenal ImpairmentUnited States
-
SanofiCompletedHepatic ImpairmentUnited States
-
SanofiCompletedNeoplasm MalignantBelgium, United States
-
SanofiCompletedHematopoietic NeoplasmAustria, Germany, Italy, Spain, United Kingdom, France, Belgium, Israel, Sweden, Australia, United States, Lithuania, Portugal, Korea, Republic of, Singapore, Taiwan, Mexico, Brazil, Canada, Hungary, Ireland, Poland, Romania, Russian... and more
-
SanofiCompletedMyelofibrosisUnited States
-
SanofiCompletedHematopoietic NeoplasmUnited States, Spain, France, Canada, Australia, Korea, Republic of, Germany, Italy, United Kingdom
-
University of WashingtonRecruitingAcute Myeloid Leukemia | Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia | Myelodysplastic Syndrome | Myeloproliferative Neoplasm | Myelodysplastic/Myeloproliferative Neoplasm | Secondary Myelofibrosis | Myeloproliferative Neoplasm, UnclassifiableUnited States